|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||0.5100 - 0.5100|
|52-week range||0.0001 - 0.5100|
|Beta (5Y monthly)||1.71|
|PE ratio (TTM)||36.43|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Allergy Therapeutics' (LON:AGY) stock is up by a considerable 48% over the past three months. We wonder if and what...
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the Year ended 30 June 2021 Record pre-R&D operating profit ahead of market expectations reflecting continued sales growth Successful ex-vivo VLP Peanut biomarker study showing 24-fold reduction in allergenicity and beneficial efficacy profile paving the way for first-in-human trial in 2022Strong cash balance of £40.3m providing sufficient funds with a small amount of debt under current assumptions to
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...